Navigation Links
Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
Date:2/24/2012

PALM SPRINGS, Calif., Feb. 24, 2012 /PRNewswire-USNewswire/ -- Results were presented today from the first study to show that the daily use of long-acting opioids increases the risk of hypogonadism (low testosterone) in men when compared to those taking short-acting opioids. These results were reported today at a poster session at the American Academy of Pain Medicine's 28th Annual Meeting.

Although this was a small retrospective study, Dr. Rubinstein believes this higher rate of hypogonadism shows that there may be some safety considerations that we were not aware of 10 years ago. "There has been a movement over the last 10 to 15 years to convert patients to long-acting opioids from short-acting opioids with the idea that they were more effective and less risky," comments Dr. Rubinstein. "This is the first study that calls into question whether or not there is a safety difference between long-acting and short-acting opioids."

Andrea Rubinstein, M.D., of the Department of Anesthesiology and Chronic Pain, Kaiser Permanente Santa Rosa Medical Center, in Santa Rosa, California, in collaboration with the Division of Research, presented the results. Since the 1970s hypogonadism in men has been linked to men using daily opioid therapy, but to date, no one has evaluated whether the risk of hypogonadism was linked to specific opioids, the duration of action of the opioid, or total daily opioid use. A small retrospective cohort study of 81 men, between the ages of 18 and 80 was conducted with men that were referred by primary care to the tertiary pain clinic. These men were on a stable dose of daily opioids for at least 90 days, and none had a previous diagnosis of hypogonadism. The study excluded patients with any known endocrine disease other than stable, treated hypothyroidism, or those with a prior diagnosis of cancer or HIV. Kaiser Foundation Research Institutional Review Board approved the study with waiver of consent.

The morning testosterone
'/>"/>

SOURCE American Academy of Pain Medicine
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
3. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
4. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
5. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
6. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
7. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
8. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
9. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
10. Zimmer and ISTO Technologies Announce Phase III Clinical Study to Evaluate the Effectiveness of Engineered Juvenile Cartilage to Repair Damaged Knees
11. Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay - Harmony Prenatal Test™ - and Publication of Study on Specimen Transport
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... OAKS, Calif. , June 19, 2013 Amgen ... the United States , Canada ... this year,s recipients of the Amgen Award for Science Teaching ... extraordinary teachers at the kindergarten through 12th grade level who ... in science education. With a long-standing commitment to ...
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... lymphoma (SLL). Ibrutinib was shown to be safe and ... in patients who were at high-risk due to factors ...
(Date:6/19/2013)...   NextDocs announced today that it will ... at DIA 2013 , the Drug Information Association ... studies that explore best practices for making the transition ... file (eTMF) systems. Sharon Ames , ... Krystyna Kowalczyk , executive vice president of clinical operations ...
Breaking Medicine Technology:Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6NextDocs and Novella to Present on eTMF at DIA 2013 2
(Date:6/19/2013)... STRATFORD, Conn (PRWEB) June 20, 2013 A man ... same man he used to be. In his debut book titled ... a war veteran who immerses himself back home, looking for the ... When Gabriel De Los Angeles, former marine from the Vietnam War, ... to take the edge off his PTSD. Wings, a wealthy acquaintance ...
(Date:6/19/2013)... Across the globe billions of people live ... the medical advances that benefit developed western society. ... and the necessary aid to help curb the conditions ... Outlook with Ben Kingsley is partnering with some ... these people live and highlight the invaluable resources being ...
(Date:6/19/2013)... 2013 HASCO Medical, Inc. (OTCBB: ... intent to purchase privately held Auto Mobility Sales, ... wheelchair accessible vehicle sales, service and rentals in ... Inc compliments and expands HASCO's strategy of becoming ... dealers . The acquisition is subject to customary ...
(Date:6/19/2013)... 2013 Kleritec, Inc. announced the addition ... http://www.kleritec.com . In the recent expansion Kleritec ... activities packages for pre-school and day care providers. The ... to aid teachers across the United States the ability ... , Included in the art and activities packages is ...
(Date:6/19/2013)... Citi Bike has come to New York City in ... to know for sure how many patients will choose to take ... the option. In fact, he’s happy about anything that might ... it more convenient for them to visit his office at 133 ... Alternative Medicine at Back and Body Medical and an experienced ...
Breaking Medicine News(10 mins):Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2Health News:HASCO Medical, Inc. to Acquire Auto Mobility Sales, Inc. 2Health News:Kleritec Announces Addition of Educational Products. 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3
... Cuts Will Reduce Access to Care for Millions ... , , ARLINGTON, Va., Sept. 16 ... recommendations for healthcare reform in his long-awaited "Chairman,s mark" version of ... home medical equipment, ranging from power wheelchairs to anti-fraud measures. The ...
... strong disapproval of contraception might be a factor , ... are higher in states with greater levels of religious ... new U.S. study suggests. , In the study, researchers ... on teen birth rates with data from the Pew ...
... , PANAMA CITY, Fla., Sept. 16 ... staff washing their hands when moving from patient to patient can ... Commission , handwashing failures contribute to healthcare-associated infections ... hospitals $4 billion to $29 billion annually to combat. At ...
... , MINNEAPOLIS, Sept. 16 Today ClearWay ... and thanked outgoing members for their service to the organization. David ... as the new Board Chair. The full roster of Board Officers ... David Fisher, Board Chair - An attorney ...
... , , , SAN DIEGO, ... Diego based medical device company, today announced that its application for ... technology has been approved by the Food and Drug Administration. The ... , , Jim Hitchin, SpectraScience,s, CEO said, ...
... InVitria to ... in Animal Cells (PEACe) in Jackson Hole, WY, Sept. 19-23. , ... Fort Collins, CO (PRWEB) September 16, 2009 -- InVitria ... supplements at the 9th Annual PEACe conference to be held in Jackson Hole, WY, Sept. ...
Cached Medicine News:Health News:Senate Finance Committee Cuts Home Medical Equipment in Reform Package 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 3Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 4Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:SpectraScience Receives FDA Approval for Enhancements to WavSTAT(R) Optical Biopsy System 2Health News:InVitria Cell Culture Product Line to Headline PEACe 2
... 1 Block MBS Start up kit. ... software and choice of 1 MultiBlock ... to 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding ...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... The latest addition to our ... cyclers is the personal-sized GeneAmp ... instrument for both basic PCR ... represents the culmination of several ...
Medicine Products: